440 related articles for article (PubMed ID: 8858891)
1. Cytochrome P450: genetic polymorphism and drug interactions.
Belpaire FM; Bogaert MG
Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
Brosen K
Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
4. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
[TBL] [Abstract][Full Text] [Related]
5. Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease.
Tanaka E
J Clin Pharm Ther; 1998 Jun; 23(3):161-70. PubMed ID: 9831966
[TBL] [Abstract][Full Text] [Related]
6. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
[TBL] [Abstract][Full Text] [Related]
9. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
Brøsen K
Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
[TBL] [Abstract][Full Text] [Related]
10. Update: genetic polymorphism of drug metabolizing enzymes in humans.
Tanaka E
J Clin Pharm Ther; 1999 Oct; 24(5):323-9. PubMed ID: 10583694
[TBL] [Abstract][Full Text] [Related]
11. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T; Price A
Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
[TBL] [Abstract][Full Text] [Related]
12. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.
Kroemer HK; Eichelbaum M
Life Sci; 1995; 56(26):2285-98. PubMed ID: 7791516
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM
Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
Linder MW; Prough RA; Valdes R
Clin Chem; 1997 Feb; 43(2):254-66. PubMed ID: 9023127
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacogenetics of oxidation reactions of drugs].
Jacqz-Aigrain E
Arch Fr Pediatr; 1989 Jan; 46(1):59-65. PubMed ID: 2653266
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
18. Genetically determined adverse drug reactions involving metabolism.
Lennard MS
Drug Saf; 1993 Jul; 9(1):60-77. PubMed ID: 8347292
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs.
Stingl J; Viviani R
J Intern Med; 2015 Feb; 277(2):167-177. PubMed ID: 25297512
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
